Reference entry
Crystagen (EDP)
EDP Tripeptide · Thymus Immune Bioregulator
Overview
Crystagen is a Khavinson bioregulator tripeptide (EDP) identified in thymalin with selective action on thymus tissues. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it enhances immune function by stimulating normal lymphocyte proliferation while inhibiting tumor cell growth. Research shows effectiveness in normalizing immunity in 82% of elderly patients (vs 56% control) and reducing respiratory infections in athletes by doubling HSP gene expression.
Crystagen works through epigenetic regulation by influencing gene expression and protein synthesis in immune cells. It regulates the synthesis of heat-shock proteins, cytokines, and affects cell differentiation, proliferation, and apoptosis. The EDP peptide enhances spontaneous proliferative activity of normal lymphocytes while inhibiting proliferation of tumor cells (K-562 erythromyelosis). It activates B-cell immune system and thymic epithelial cells (VTEC2.H/S).
Normalizes immunogram in elderly patients with impaired immunity.
Restores immune function after infectious diseases.
Helps normalize immunity after radiation and chemotherapy exposure.
Increases stress resistance and reduces respiratory infections in athletes.
Mechanism
Crystagen is a Khavinson bioregulator tripeptide (EDP) identified in thymalin with selective action on thymus tissues. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it enhances immune function by stimulating normal lymphocyte proliferation while inhibiting tumor cell growth. Research shows effectiveness in normalizing immunity in 82% of elderly patients (vs 56% control) and reducing respiratory infections in athletes by doubling HSP gene expression.
Crystagen works through epigenetic regulation by influencing gene expression and protein synthesis in immune cells. It regulates the synthesis of heat-shock proteins, cytokines, and affects cell differentiation, proliferation, and apoptosis. The EDP peptide enhances spontaneous proliferative activity of normal lymphocytes while inhibiting proliferation of tumor cells (K-562 erythromyelosis). It activates B-cell immune system and thymic epithelial cells (VTEC2.H/S).
Normalizes immunogram in elderly patients with impaired immunity.
Research areas
- Crystagen is a Khavinson bioregulator tripeptide (EDP) identified in thymalin with selective action on thymus tissues. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it enhances immune function by stimulating normal lymphocyte proliferation while inhibiting tumor cell growth. Research shows effectiveness in normalizing immunity in 82% of elderly patients (vs 56% control) and reducing respiratory infections in athletes by doubling HSP gene expression.
- Crystagen works through epigenetic regulation by influencing gene expression and protein synthesis in immune cells. It regulates the synthesis of heat-shock proteins, cytokines, and affects cell differentiation, proliferation, and apoptosis. The EDP peptide enhances spontaneous proliferative activity of normal lymphocytes while inhibiting proliferation of tumor cells (K-562 erythromyelosis). It activates B-cell immune system and thymic epithelial cells (VTEC2.H/S).
- Normalizes immunogram in elderly patients with impaired immunity.
- Restores immune function after infectious diseases.
- Helps normalize immunity after radiation and chemotherapy exposure.
- Increases stress resistance and reduces respiratory infections in athletes.
- Doubles expression of heat-shock protein gene HSPA1A.
- Inhibits proliferation of K-562 human erythromyelosis tumor cells.
Research notes
- Generally well-tolerated
- Minimal side effects reported
- Allergic reactions
- Unusual immune symptoms
- Active autoimmune flares (consult physician)
- Known hypersensitivity
- Pregnancy or breastfeeding
Pharmacokinetics
- Helps normalize immunity after radiation and chemotherapy exposure.
FAQs
Does Crystagen actually help athletes reduce respiratory infections?
Yes, research shows Crystagen doubled HSP gene expression in athletes and reduced respiratory infections in a study population. By enhancing heat-shock protein production and normalizing IL-6 expression, it strengthens immune resilience during heavy training stress when illness risk is elevated.
What percentage of elderly patients experience immune improvements with Crystagen?
Clinical research found Crystagen normalized immune function (immunogram) in 82% of elderly patients versus only 56% in the control group. This significant difference suggests it effectively reverses age-related immune decline, though results vary individually.
Is Crystagen safe to use if I have an active autoimmune condition?
Crystagen is an immune-stimulating peptide that may exacerbate active autoimmune flares since it enhances lymphocyte proliferation and immune activation. Medical consultation is essential before using, especially during autoimmune disease flares. It's better suited for those with immunodeficiency than autoimmunity.
Can Crystagen help protect immune function after chemotherapy?
Yes, research shows Crystagen effectiveness for normalizing immunity after chemotherapy and radiation exposure. As a thymus-derived immune bioregulator, it supports recovery of lymphocyte populations and immune surveillance that are suppressed by cancer treatments.